1 / 12

Influenza Vaccine Responses

Influenza Vaccine Responses. Zhiping Ye, M.D., Ph.D. Division of Viral Products. Prepared for Vaccines and Related Biological Products Advisory Committee 17 February 2006. 1. 2005-2006 Vaccine Responses to Recent Influenza isolates.

marny-morse
Download Presentation

Influenza Vaccine Responses

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee 17 February 2006 1

  2. 2005-2006 Vaccine Responses to Recent Influenza isolates • Panels of sera obtained from 2005-2006 influenza vaccinees were tested for their ability to inhibit heamagglutination of current influenza isolates • Post-vaccination antibody titer of current virus isolates compared to vaccine strain of virus (bold) • Lower titers (italic) indicate poor antibody inhibition of tested virus isolates 2

  3. Serum Panels for Serologies 1. AUSTRALIA IAN BARR, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) WHO, AUSTRALIA ELDERLY A/WELLINGTON/01/04 (H3N2) B/JIANSU/10/03 2. EUROPE JOHN WOOD, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIBSC, ENGLAND ELDERLY A/NEW YORK/55/04 (H3N2) B/JIANGSU/10/03 3. JAPAN TAKATO ODIGARI, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIID, JAPAN ELDERLY A/NEW YORK/55/04 (H3N2) B/SHANGHAI/361/02 4. STEFAN GRAVENSTEIN, M.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA ELDERLY A/NEW YORK/55/04 (H3N2) MEDICAL SCHOOL, PEDIATRIC B/JIANGSU/10/03 USA 3

  4. ANTIGENS FOR SEROLOGIES (H3N2) VACCINE STRAIN A/New York/55/04 X-157 REPRESENTATIVE CURRENT STRAINS • A/Wisconsin/76/05 • A/Hiroshima/52/05 • A/Anhui/1239/05 • A/Brazil/1742/05 • A/North Carolina/13/05 • A/Sydney/545/05 • A/Lyon/21/06 • A/Norway/28/06 • A/Gunama/16/05 • A/Nagasaki/50/05 4

  5. HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT2005-2006 INFLUENZA VACCINEPEDIATRIC POPULATION 5

  6. HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT2005-2006 INFLUENZA VACCINEADULT POPULATION ( CBER ) 6

  7. A/NEW YORK/55/2004 VACCINESSUMMARY TABLE (ADULT)VIRUSES WITH > 50% GMT REDUCTION 7

  8. ANTIGENS FOR SEROLOGIES (B) VACCINE STRAIN B/JIANGSU/10/2003* REPRESENTATIVE CURRENT STRAINS B/FLORIDA/7/2004* B/KITAKYUSYU/5/2005* B/GANSU/9/2005* B/PHILIPPINES/1401/2005* B/MADAGASCAR/1509/2005* B/EGYPT/144/2005* B/MALAYSIA/2506/2004+B/OHIO/1/2005+ B/GUANGONG/321/2005+ B/ENGLAND/458/2005+ B/SINGAPORE/21/2005+ * B/YAMAGATA LINEAGE + B/VICTORIA LINEAGE 8

  9. HI ANTIBODY RESPONSES TO THE B COMPONENT2005-2006 INFLUENZA VACCINEPEDIATRIC POPULATION 9

  10. HI ANTIBODY RESPONSES TO THE B COMPONENT2005-2006 INFLUENZA VACCINEADULT POPULATION (CDC) 10

  11. B/JANGSU/10/2003-LIKE VACCINESSUMMARY TABLEVIRUSES WITH > 50% GMT REDUCTION (ADULT) 11

  12. Influenza Vaccine ResponsesSummary Studies with sera collected after immunization with current vaccines show that: • H1 • Representative recent viruses well inhibited (data not shown) • H3 • A/WISCONSIN/67/2005 (H3N2)-like viruses less well inhibited compared to the vaccine strain • B • B/YAMAGATA/16/88-lineage • Representative recent viruses generally well inhibited compared to the vaccine strain • B/VICTORIA/2/87-lineage • Representative B/Malaysia/2506/2004-like viruses poorly inhibited compared to the vaccine strain 12

More Related